BioScience Health Innovations 3Q 2026: Revenue $970.07K, EPS ($0.01) — 10-Q Summary
BioScience Health Innovations reported 3Q 2026 revenue of $970.07K, down 14% YoY, and a net loss of $149,225, wider than the prior year's $8,782. Operating expenses increased to $785,824 due to exchange-listing costs, marketing, R&D, and other factors. Management remains confident in projected growth.
How this was made

The 30-second read
Why it matters
The filing provides the first public disclosure of the company's latest financial performance, offering a baseline for valuation and liquidity considerations.
Market read
While the numbers are modest, the filing is the first public release of the quarter's data, useful for niche investors.
What to watch
Potential upcoming exchange listing could unlock liquidity and valuation upside.
Background
BioScience Health Innovations filed its 10‑Q for Q3 2026, reporting a 14% revenue decline and widened net loss.
Market effects
None significant; micro‑cap biotech sector impact minimal.
No discernible regional effect.
Limited to investors tracking small‑cap SEC filings.
Counterpoint
The modest revenue decline may be temporary; investors could view the expense increase as a long‑term growth investment.
Key entities
- companyBioScience Health Innovations, Inc.
Micro‑cap biotech firm reporting Q3 2026 results.



